Nicki Thompson
CEO Trimtech Therapeutics
Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and commercial leadership roles. She is CEO of Cambridge-based TRIMTECH Therapeutics (an MRC LMB/UK DRI spin-out), which focuses on a novel targeted protein degradation (TPD) approach to treat neurodegenerative diseases. Nicki led TRIMTECH through its recent $31M seed financing. Nicki was also founding CEO of Amphista Therapeutics, leading the company through its series A and B financings and spearheaded Amphista’s collaborations with BMS and Merck KGaA. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and prior to that, Senior Director, Business Development for GSK’s external drug discovery and external innovation groups. Nicki’s Biotech experience also includes her roles as CBO, then Chair of the Board for Nanna Therapeutics Ltd (acquired by Astellas Pharma Inc.) and Chair of the Board for Camena Bioscience. She holds a PhD in Cell Biology from University College London
Seminars
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
- Why TRIM 21 is ideally suited to selectively degrading protein aggregates which underpin so many neurodegenerative diseases
- TrimTech’s approach to validating targets and TRIM21’s role in degrading these targets with a range of modalities
- TrimTech’s strategies and progress developing therapeutic degraders known as a TRIMTACTM or TRIMGLUETM for neurodegenerative and inflammatory diseases
